Kerala has become the first state in India to provide public funding for pneumonia vaccines aimed at adults from economically disadvantaged backgrounds. This initiative seeks to address the significant mortality rates attributed to severe respiratory infections among the elderly population. By introducing adult vaccination programs targeted at vulnerable segments, Kerala has generated discussion about the potential for similar initiatives to be implemented in other states and at the national level.

Investment in Elderly Health

The state has earmarked Rs 50 crore for the vaccination of individuals aged 60 and above who live below the poverty line, utilizing the pneumococcal vaccine. Pneumonia ranks as a leading cause of death and hospitalization not only among the elderly but also among children under five in India. While the government offers vaccinations to younger children through its universal immunization scheme, no such provisions exist for older adults, highlighting a critical gap in public health policy.

Health Risks for the Elderly

Scientific studies indicate that pneumonia presents a significant health risk for the elderly demographic in India. The mortality rates associated with community-acquired pneumonia (CAP) in individuals over 65 range from 10 to 30 percent, with figures nearing 50 percent in cases related to hospital-acquired infections. Experts emphasize the importance of addressing this public health issue through preventive measures such as vaccinations.

Expert Opinions on Vaccination

A doctor remarked on the complications that arise for older adults suffering from existing comorbidities such as heart disease, diabetes, and hypertension. The combination of infections and pre-existing health conditions raises the likelihood of severe health complications and mortality. As a result, effective vaccination strategies are essential for safeguarding this vulnerable population.

Current Vaccination Options

The Pneumococcal Conjugate Vaccine 20 (PCV20), also known as Prevnar 20, is currently recommended by most pulmonologists. This vaccine protects against 20 pneumococcal serotypes and is advantageous because it requires only a single dose in a lifetime, thus simplifying the vaccination protocol. The market cost for this vaccine ranges from Rs 4,400 to Rs 5,500 per dose when purchased privately.

Eligibility and Effectiveness

Health professionals advocate for vaccinations for all individuals above 50 years, particularly those who are transplant recipients or suffer from chronic illnesses. This demographic is at a heightened risk for severe respiratory infections, including pneumonia. The vaccine is reported to provide a 45 to 75 percent effectiveness rate in mitigating the risk of pneumonia, likely reducing hospitalizations and severe complications.

Potential Nationwide Impact

Experts believe that Kerala’s initiative could serve as a model for other states, potentially leading to the expansion of adult vaccination programs across India. Such measures may enhance preventive healthcare practices and promote healthier aging among the population. Nevertheless, several factors hinder the widespread adoption of adult vaccinations, including vaccine skepticism, limited public awareness, and the high costs associated with vaccines.

Challenges to Implementation

A significant barrier to adult immunization is the lack of a unified national guideline concerning adult vaccination. While various medical bodies have issued recommendations, discrepancies among them create confusion regarding the appropriate vaccines and age thresholds for administration. Improving vaccine coverage among adults necessitates a comprehensive approach, including clear guidelines and increased public awareness to encourage proactive healthcare practices.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share